ImmuniQ
IM
About
ImmuniQ is an immuno-oncology company focused on improving the efficacy of immune checkpoint inhibitors. They have developed a novel method to assess the functional activity of a patient's cancer cells, aiming to predict which patients will benefit from these treatments, thereby optimizing therapeutic outcomes.
Key facts
At-a-glance profile data
- Website
- immuniq.tech
- Headquarters
- Tel Aviv, Israel
- Founded
- 2021
- Total funding
- -
- Business model
- B2B
Add first review
Frequently asked
What is ImmuniQ's current status?
ImmuniQ's current operating status is: Inactive.